Open AccessJournal Article
Long-acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient's perspective.
TLDR
The aim of this review is to summarize the biological bases, the available information on completed and ongoing clinical trials and the potential development of long-acting regimens for the treatment and prevention of HIV infection.Abstract:
Current cART regimens are highly potent and well tolerated, but long-term toxicities, drug-drug interactions, lifetime costs and scarce option for multiclass failed patients could limit the efficacy of treatment itself. Long-acting formulations of antiretrovirals, which could potentially replace daily tablets, have been developed and are under investigation for prevention and treatment of HIV infection. Cabotegravir and rilpivirine represent the first drugs studied in this context. The aim of this review is to summarize the biological bases, the available information on completed and ongoing clinical trials and the potential development of long-acting regimens for the treatment and prevention of HIV infection.read more
Citations
More filters
Journal ArticleDOI
Multimodal theranostic nanoformulations permit magnetic resonance bioimaging of antiretroviral drug particle tissue-cell biodistribution
Bhavesh D. Kevadiya,Christopher Woldstad,Brendan M. Ottemann,Prasanta K. Dash,Balasrinivasa R. Sajja,Benjamin G. Lamberty,Brenda Morsey,Ted Kocher,Rinku Dutta,Aditya N. Bade,Yutong Liu,Shannon Callen,Howard S. Fox,Siddappa N. Byrareddy,JoEllyn M McMillan,Tatiana K. Bronich,Benson J Edagwa,Michael D. Boska,Howard E. Gendelman +18 more
TL;DR: It is posited that these theranostic nanoprobes can assess LASER ART drug delivery and be used as part of a precision nanomedicine therapeutic strategy.
Journal ArticleDOI
Treatment and prevention of HIV infection with long-acting antiretrovirals
Laura Benítez-Gutiérrez,Vicente Soriano,Silvia Requena,Ana Arias,Pablo Barreiro,Carmen de Mendoza +5 more
TL;DR: In the absence of eradicative therapy for individuals with HIV infection and protective vaccines for persons at risk, the advent of long-acting antiretrovirals will expand options for overcoming the challenge of suboptimal drug adherence and reduce the burden of HIV infection.
Journal ArticleDOI
Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV
Jane M. Simoni,Kristin Beima-Sofie,Zahra H Mohamed,Joan Christodoulou,Kenneth Tapia,Susan M. Graham,Rodney J. Y. Ho,Ann C. Collier +7 more
TL;DR: Potential users considered LAI-ART generally acceptable yet voiced possible concerns as well, especially if their current pill-based regimen was effective in achieving viral suppression, and parents' interest varied according to their child's age and sensitivity to injections.
Journal ArticleDOI
Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection.
TL;DR: The study evaluates the acceptability and preferences for long-acting antiretroviral therapy (LA-ART) among a diverse cohort of people with HIV infection (PWH) and indicates a willingness to use new LA ART formulations.
Journal ArticleDOI
Emerging reverse transcriptase inhibitors for HIV-1 infection.
TL;DR: GS-9131, MK-8591, Elsulfavirine and Doravirines are four new agents that are furthest along in development that show promise and potential to improve ART in the future.
References
More filters
Journal ArticleDOI
Preexposure Prophylaxis for HIV Infection among African Women
Lut Van Damme,Amy Corneli,Khatija Ahmed,Johan Lombaard,Saidi Kapiga,Mookho Malahleha,Rachel Manongi,Jacob Onyango,Lucky Temu,Modie Constance Monedi,Mankalimeng Makanda,Lisa Saylor,Haddie Kiernan,Stella Kirkendale,Christina Wong,Robert M. Grant,Angela D. M. Kashuba,Kavita Nanda,Justin Mandala,Katrien Fransen,Jennifer Deese,Tania Crucitti,Timothy D Mastro,Douglas Taylor +23 more
TL;DR: Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was associated with increased rates of side effects, as compared with placebo, and drug adherence appeared to be low.
Journal ArticleDOI
Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women
Jeanne M. Marrazzo,Gita Ramjee,Barbra A. Richardson,Kailazarid Gomez,Nyaradzo Mgodi,Gonasagrie Nair,Thesla Palanee,Clemensia Nakabiito,Ariane van der Straten,Lisa M. Noguchi,Craig W. Hendrix,James Y. Dai,S. Ganesh,Baningi Mkhize,Marthinette Taljaard,Urvi M. Parikh,Jeanna M. Piper,Benoît Mâsse,Benoît Mâsse,Cynthia I. Grossman,James F. Rooney,Jill L. Schwartz,Heather Watts,Mark A. Marzinke,Sharon L. Hillier,Ian McGowan,Z. Mike Chirenje +26 more
TL;DR: None of the drug regimens evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis, and adherence to study drugs was low.
Journal ArticleDOI
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
Journal ArticleDOI
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Sharon Walmsley,Antonio Antela,Nathan Clumeck,Dan Duiculescu,Andrea Eberhard,Felix Gutieŕrez,Laurent Hocqueloux,Franco Maggiolo,Uriel Sandkovsky,Catherine Granier,Keith A. Pappa,Brian Wynne,Sherene Min,Garrett Nichols +13 more
TL;DR: Dolutegravir plus abacavir-lamivudine had a better safety profile and was more effective through 48 weeks than the regimen with efavirenz-tenofovir DF-emtricitabine, thus meeting the criterion for superiority.
Journal ArticleDOI
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Marina Caskey,Florian Klein,Julio C. C. Lorenzi,Michael S. Seaman,Anthony P. West,Noreen Buckley,Gisela Kremer,Lilian Nogueira,Malte Braunschweig,Johannes F. Scheid,Joshua A. Horwitz,Irina Shimeliovich,Sivan Ben-Avraham,Maggi Witmer-Pack,Martin Platten,Clara Lehmann,Leah A. Burke,Thomas Hawthorne,Robert J. Gorelick,Bruce D. Walker,Tibor Keler,Roy M. Gulick,Gerd Fätkenheuer,Sarah J. Schlesinger,Michel C. Nussenzweig +24 more
TL;DR: It is concluded that, as a single agent, 3BNC117 is safe and effective in reducing HIV-1 viraemia, and that immunotherapy should be explored as a new modality for HIV- 1 prevention, therapy and cure.
Related Papers (5)
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A. Margolis,Juan González-García,Hans Jürgen Stellbrink,Joseph J. Eron,Yazdan Yazdanpanah,Daniel Podzamczer,Thomas A. Lutz,Jonathan B. Angel,Gary Richmond,Bonaventura Clotet,Félix Gutiérrez,Louis Sloan,Marty St. Clair,Miranda Murray,Susan L. Ford,Joseph M. Mrus,Parul Patel,Herta Crauwels,Sandy Griffith,Kenneth Sutton,David Dorey,Kimberly Y. Smith,Peter Williams,William Spreen +23 more